Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Clinical Trial Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Primary Sclerosing Cholangitis
Conditions
Interventions
Obeticholic Acid (OCA)
Placebo
Locations
36
United States
St. Joseph's Hospital & Medical Center
Phoenix, Arizona, United States
Mayo Clinic
Phoenix, Arizona, United States
University of California Davis Medical Center
Sacramento, California, United States
University of Colorado, Denver
Aurora, Colorado, United States
University of Miami Hospital
Miami, Florida, United States
Piedmont Atlanta Georgia Transplant Institute
Atlanta, Georgia, United States
Start Date
February 9, 2015
Primary Completion Date
March 7, 2017
Completion Date
March 22, 2018
Last Updated
July 8, 2021
NCT06026865
NCT01161992
NCT06686810
NCT06037577
NCT03766035
NCT05082779
Lead Sponsor
Intercept Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions